Connect with us

Government

Best Penny Stocks to Buy Now? 3 Trump Stocks to Watch in January

These penny stocks could be worth watching as Trump stocks climb
The post Best Penny Stocks to Buy Now? 3 Trump Stocks to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

3 Penny Stocks For Your Mid January Watchlist as Trump Stocks Rise

If you’re making a penny stocks watchlist right now, there are hundreds of options to choose from. While it can be difficult to pick just a handful for your list, by understanding what’s going on in the stock market it can be much easier. Right now, there are a lot of factors that are impacting how penny stocks trade. 

First and foremost we have the pandemic and the Omicron variant specifically. This has wreaked havoc across world markets for the last month or so. Next, we have the changing economy in the U.S., which includes the recent Fed minutes, unemployment numbers, and high inflation. 

All of these are contributing greatly to how penny stocks trade and how they will trade in the near future. With penny stocks, we tend to see speculation be much higher than that of blue chips. And because of this, knowing how to take advantage of what’s impacting the market, is crucial. 

[Read More] 4 Top Penny Stocks To Buy Right Now According To Insiders

Lastly, having a thorough understanding of how to trade penny stocks, will always be a major benefit to your trading. Because penny stocks move so quickly, this can quickly mean the difference between profits and losses. 

When it comes to Trump stocks, we’ve seen a sizable amount of momentum during certain trading days over the past year. This includes companies like Digital World Acquisition Corp. (NASDAQ: DWAC) and Phunware Inc. (NASDAQ: PHUN), which have both climbed substantially in relation to the former President. So, while they are popular, they are also highly volatile. So, with all of that in mind, let’s take a look at three penny stocks for your mid-January watchlist. 

3 Penny Stocks to Watch in January 2022

  1. Lloyds Banking Group plc (NYSE: LYG
  2. Kaival Brands Innovations Group Inc. (NASDAQ: KAVL
  3. Kosmos Energy Ltd. (NYSE: KOS

Lloyds Banking Group plc (NYSE: LYG) 

Up by almost 4% at EOD on January 6th are shares of LYG stock. And, in the past five days, shares have climbed by over 11% and more than 16% in the past month. Over the last twelve months, shares have shot up by over 41%, which helps to explain why the company is so popular right now. 

If you’re not familiar, Lloyds is a pure-play financial services company that offers banking and a range of insurance/wealth services. Right now, one of the largest impacts on the finance industry is Covid and the Omicron variant. Because the pandemic is still going on, many expect the finance sector to continue taking a hit. 

However, if we can see an economic recovery begin, we could see the banking industry come back strong. While there is a lot of uncertainty with a penny stock like LYG, its business truly depends on what happens in both the U.K. and global economy. But, with its sizable twelve-month gain, many investors are keeping a close eye on the company. Considering this, will it be on your list of penny stocks to watch?

Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) 

One of the largest gainers of the day so far is KAVL stock, pushing up by over 24% at EOD. While shares are still down by around 90% for the twelve-month period, we are seeing this slight bullish rise occurring in the past few trading days. 

[Read More] Energy Penny Stocks Are Climbing Today, Here’s 3 to Watch And Why

So, why exactly is KAVL stock moving right now? Well, there is no company-specific news that could help to identify today’s move with KAVL stock, however, it did make an announcement only a few weeks ago. On December 14th, the company stated that U.K. smokers preferred its Bidi Vapor E-Cigs over rivals. 

“While the U.S. e-cigarette market numbers have shown that consumers prefer the BIDI® Stick, we are ecstatic to see that the U.K. market research results confirms that the 2% nicotine BIDI® Stick is similarly preferred by adult e-cigarette users and smokers in the U.K.” 

The CEO of Bidi Vapor and Kaival Brands, Niraj Patel

This is big news for the company and should help with adoption in the long term. Considering that, will it earn a spot on your penny stocks watchlist moving forward?

Penny_Stocks_to_Watch_Kaival

Kosmos Energy Ltd. (NYSE: KOS) 

Another big gainer of the day on January 6th is KOS stock. By EOD, shares of KOS had joined the bullish run on other energy penny stocks with an 8% rise. This brings its five day gain to over 24%. While this may not seem like a lot, we have to consider the rest of the stock market’s trajectory during that time. 

Now, no news came out today to help explain this gain, however, as stated earlier there is a lot of bullish sentiment in the energy industry right now. In addition, many investors believe that Kosmos could finally move toward profitability in 2022 or at least breaking even. 

In the full 2021 financial year, the company posted a trailing twelve-month loss of around $169 million. However, the market consensus is that Kosmos Energy could break-even and even turn a profit in 2022. Early estimates show a potential profit of around $270 million, however, this is purely an estimate. So, with all of this in mind, do you think that KOS stock is worth buying right now?

Penny_Stocks_to_Watch_Kosmos

Which Penny Stocks Are You Watching Right Now?

Because there is so much going on in the stock market, understanding exactly how to trade is extremely important. In addition to this, knowing who you are as an investor is crucial.

This can quickly mean the difference between picking the right penny stocks for your goals and the wrong ones. In 2022, we are still seeing a sizable amount of volatility which is mostly due to the Omicron variant and the U.S. economy. 

[Read More] Hot Penny Stocks to Watch Right Now That Are Moving in Premarket

Both of these continue to result in large intraday fluctuations with stocks of all types. So, keeping a close eye on the news, updates, and important announcements, can give you an upper hand when it comes to trading. So, with all of this in mind, which penny stocks are you watching right now?


If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!


The post Best Penny Stocks to Buy Now? 3 Trump Stocks to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Government

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide…

Published

on

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide Black Lives Matter riots in the summer of 2020, some elite colleges and universities shredded testing requirements for admission. Several years later, the test-optional admission has yet to produce the promising results for racial and class-based equity that many woke academic institutions wished.

The failure of test-optional admission policies has forced Dartmouth College to reinstate standardized test scores for admission starting next year. This should never have been eliminated, as merit will always prevail. 

"Nearly four years later, having studied the role of testing in our admissions process as well as its value as a predictor of student success at Dartmouth, we are removing the extended pause and reactivating the standardized testing requirement for undergraduate admission, effective with the Class of 2029," Dartmouth wrote in a press release Monday morning. 

"For Dartmouth, the evidence supporting our reactivation of a required testing policy is clear. Our bottom line is simple: we believe a standardized testing requirement will improve—not detract from—our ability to bring the most promising and diverse students to our campus," the elite college said. 

Who would've thought eliminating standardized tests for admission because a fringe minority said they were instruments of racism and a biased system was ever a good idea? 

Also, it doesn't take a rocket scientist to figure this out. More from Dartmouth, who commissioned the research: 

They also found that test scores represent an especially valuable tool to identify high-achieving applicants from low and middle-income backgrounds; who are first-generation college-bound; as well as students from urban and rural backgrounds.

All the colleges and universities that quickly adopted test-optional admissions in 2020 experienced a surge in applications. Perhaps the push for test-optional was under the guise of woke equality but was nothing more than protecting the bottom line for these institutions. 

A glimpse of sanity returns to woke schools: Admit qualified kids. Next up is corporate America and all tiers of the US government. 

Tyler Durden Mon, 02/05/2024 - 17:20

Read More

Continue Reading

International

Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…

Published

on

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading

International

Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….

Published

on

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com 


Read More

Continue Reading

Trending